Effects of Mevastatin on Grafted Bone in MRL/MpJ Mice

REFERENCES

• Wozney, J.M., Rosen, V., Celeste, A.J., Mitsock, L.M., Whitters, M.J., Kriz, R.W., Hewick, R.M., and Wang, E.A. (1988). Novel regulators of bone formation: molecular clones and activities. Science, 242:1528–1534.
   PubMed Web of Science ®Google Scholar
• Chikazu, D., Li, X., Kawaguchi, H., Sakuma, Y., Voznesensky, O.S., Adams, D.J., Xu, M., Hoshi, K., Katavic, V., Herschman, H.R., Raisz, L.G., and Pilbeam, C.C. (2002). Bone morphogenetic protein 2 induces cyclo-oxygenase 2 in osteoblasts via a Cbfa1 binding site: role in effects of bone morphogenetic protein 2 in vitro and in vivo. J. Bone Miner. Res., 17:1430–1440.
   PubMed Web of Science ®Google Scholar
• Mundy, G., Garrett, R., Harris, S., Chan, J., Chen, D., Rossini, G., Boyce, B., Zhao, M., and Gutierrez, G. (1999). Stimulation of bone formation in vitro and in rodents by statins. Science, 286:1946–1949.
   PubMed Web of Science ®Google Scholar
• Grundy, S.M. (1988). HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N. Engl. J. Med., 319:24–33.
   PubMed Web of Science ®Google Scholar
• Endo, A., Kuroda, M., and Tsujita, Y. (1976). ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J. Antibiot., 29:;1346–1348.
   PubMed Web of Science ®Google Scholar
• Endo, A., Tsujita, Y., Kuroda, M., and Tanzawa, K. (1977). Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Eur. J. Biochem., 77:31–36.
   PubMedGoogle Scholar
• Edwards, C.J., Hart, D.J., and Spector, T.D. (2000). Oral statins and increased bone-mineral density in postmenopausal women. Lancet, 355:2218–2219.
   PubMed Web of Science ®Google Scholar
• Lupattelli, G., Scarponi, A.M., Vaudo, G., Siepi, D., Roscini, A.R., Gemelli, F., Pirro, M., Latini, R.A., Sinzinger, H., Marchesi, S., and Mannarino, E. (2004). Simvastatin increases bone mineral density in hypercholesterolemic postmenopausal women. Metabolism, 53:744–748.
   PubMed Web of Science ®Google Scholar
• Chung, Y.S., Lee, M.D., Lee, S.K., Kim, H.M., and Fitzpatrick, L.A. (2000). HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J. Clin. Endocrinol. Metab., 85:1137–1142.
   PubMed Web of Science ®Google Scholar
• Solomon, D.H., Finkelstein, J.S., Wang, P.S., and Avorn, J. (2005). Statin lipid-lowering drugs and bone mineral density. Pharmacoepidemiol. Drug Saf., 14:219–226.
   PubMed Web of Science ®Google Scholar
• Chan, K.A., Andrade, S.E., Boles, M., Buist, D.S., Chase, G.A., Donahue, J.G., Goodman, M.J., Gurwitz, J.H., LaCroix, A.Z., and Platt, R. (2000). Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet, 355:2185–2188.
   PubMed Web of Science ®Google Scholar
• Meier, C.R., Schlienger, R.G., Kraenzlin, M.E., Schlegel, B., and Jick, H. (2000). HMG-CoA reductase inhibitors and the risk of fractures. JAMA, 283:3205–3210.
   PubMed Web of Science ®Google Scholar
• Wang, P.S., Solomon, D.H., Mogun, H., and Avorn, J. (2000). HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA, 283:3211–3216.
   PubMed Web of Science ®Google Scholar
• Rejnmark, L., Olsen, M.L., Johnsen, S.P., Vestergaard, P., Sorensen, H.T., and Mosekilde, L. (2004). Hip fracture risk in statin users—a population-based Danish case-control study. Osteopor. Int., 15:452–458.
   PubMed Web of Science ®Google Scholar
• Schoofs, M.W., Sturkenboom, M.C., Van Der Klift, M., Hofman, A., Pols, H.A., and Stricker, B.H. (2004). HMG-CoA reductase inhibitors and the risk of vertebral fracture. J. Bone Miner. Res., 19:1525–1530.
   PubMed Web of Science ®Google Scholar
• Wong, R.W., and Rabie, A.B. (2005). Histologic and ultrastructural study on statin graft in rabbit skulls. J. Oral Maxillofac. Surg., 63:1515–1521.
   PubMed Web of Science ®Google Scholar
• Nyan, M., Sato, D., Oda, M., Machida, T., Kobayashi, H., Nakamura, T., and Kasugai, S. (2007). Bone formation with the combination of simvastatin and calcium sulfate in critical-sized rat calvarial defect. J. Pharmacol. Sci., 104:384–386.
   PubMed Web of Science ®Google Scholar
• Luckman, S.P., Hughes, D.E., Coxon, F.P., Graham, R., Russell, G., and Rogers, M.J. (1998). Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone. Miner. Res., 13:581–589.
   PubMed Web of Science ®Google Scholar
• Woo, J.T., Kasai, S., Stern, P.H., and Nagai, K. (2000). Compactin suppresses bone resorption by inhibiting the fusion of prefusion osteoclasts and disrupting the actin ring in osteoclasts. J. Bone Miner. Res., 15:650–662.
   PubMed Web of Science ®Google Scholar
• Hirotani, H., Ohtsuka-Isoya, M., Mori, S., Sakai, R., Eto, Y., Echigo, S., and Shinoda, H. (2002). Activin A increases the bone mass of grafted bone in C3H/HeJ mice. Calcif. Tissue Int., 70:330–338.
   PubMed Web of Science ®Google Scholar
• Shoji, K., Horiuchi, H., and Shinoda, H. (1995). Inhibitory effects of a bisphosphonate (risedronate) on experimental periodontitis in rats. J. Periodontal. Res., 30:277–284.
   PubMed Web of Science ®Google Scholar
• Prockop, D.J. (1997). Marrow stromal cells as stem cells for nonhematopoietic tissues. Science, 276:71–74.
   PubMed Web of Science ®Google Scholar
• Ji, X., Chen, D., Xu, C., Harris, S.E., Mundy, G.R., and Yoneda, T. (2000). Patterns of gene expression associated with BMP-2-induced osteoblast and adipocyte differentiation of mesenchymal progenitor cell 3T3-F442A. J. Bone Miner. Metab., 18:132–139.
   PubMed Web of Science ®Google Scholar
• Maeda, T., Matsunuma, A., Kurahashi, I., Yanagawa, T., Yoshida, H., and Horiuchi, N. (2004). Induction of osteoblast differentiation indices by statins in MC3T3-E1 cells. J. Cell. Biochem., 92:458–471.
   PubMed Web of Science ®Google Scholar
• Itoh, K., Udagawa, N., Katagiri, T., Iemura, S., Ueno, N., Yasuda, H., Higashio, K., Quinn, J.M., Gillespie, M.T., Martin, T.J., Suda, T., and Takahashi, N. (2001). Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand. Endocrinology, 142:3656–3662.
   PubMed Web of Science ®Google Scholar
• Kaneko, H., Arakawa, T., Mano, H., Kaneda, T., Ogasawara, A., Nakagawa, M., Toyama, Y., Yabe, Y., Kumegawa, M., and Hakeda, Y. (2000). Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts. Bone, 27:479–486.
   PubMed Web of Science ®Google Scholar